IQVIA Holdings, Inc.
IQV
Positions held
Your positionsIQV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- IQVIA Holdings operates in the growing healthcare diagnostics and research industry, which is expected to expand as demand for data-driven healthcare solutions increases.
- Revenue increased by 5% compared to the prior quarter, reaching $4.4 billion.
- Gross margin improved to 32.9%, up from 32.6% in the previous quarter.
- The company's earnings growth has been negative at -0.6%, indicating potential challenges in profitability.
- The trailing P/E ratio stands at 32.3, suggesting the stock may be overvalued compared to its earnings growth.
- The debt-to-equity ratio is high at 257.98, which may pose risks in a rising interest rate environment.
Fundamentals
| Market cap | $42.61B | Enterprise value | $56.92B | Trailing P/E | 32.16 | Forward P/E | 17.94 |
| PEG | 0.94 | Price / book | 6.91 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | 8.7% | Earnings growth | -0.6% | Gross margin | 33.0% | Operating margin | 13.0% |
| Profit margin | 8.1% | ROE | 22.8% | ROA | 5.1% | Debt / equity | 2.58 |
| Current ratio | 0.71 | Free cash flow | $2.15B | Analyst recommendation | strong_buy | Mean target | $293.74 |
| 52w high | $277.40 | 52w low | $154.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4B | $4.2B | $4.4B | $4.1B | $4.0B | — |
| Op margin | 13.0% | 13.6% | 14.9% | 14.0% | 13.4% | — |
| Net income | $256M | $274M | $514M | $331M | $266M | — |
| Gross margin | 32.9% | 32.6% | 32.9% | 33.5% | 32.9% | — |
| Gross profit | $1.4B | $1.4B | $1.4B | $1.4B | $1.3B | — |
| Operating income | $569M | $565M | $651M | $573M | $538M | — |
- Revenue +5% vs prior quarter ($4.4B vs $4.2B).
- Gross margin 32.9% (was 32.6% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $16.3B | $15.4B | $15.0B | $14.4B | — |
| Op margin | 14.0% | 14.7% | 13.8% | 12.7% | — |
| Net income | $1.4B | $1.4B | $1.4B | $1.1B | — |
| Gross margin | 33.3% | 34.9% | 35.0% | 34.9% | — |
| Gross profit | $5.4B | $5.4B | $5.2B | $5.0B | — |
| Operating income | $2.3B | $2.3B | $2.1B | $1.8B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Could You Have Seen The Run In Tempus AI Stock Coming?
2026-10-08 · Leerink Partners Adjusts IQVIA Holdings Price Target to $310 From $280
2026-10-07 · IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
2026-10-07 · IQVIA Launches Explorer for Commercial Decision-Making
2026-10-07 · IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
2026-10-07 · Mizuho Adjusts Price Target on IQVIA Holdings to $300 From $275
2026-10-06 · Barclays Adjusts IQVIA Holdings Price Target to $300 From $275, Maintains Overweight Rating
2026-10-06 · Evercore ISI Adjusts Price Target on IQVIA Holdings to $290 From $275, Maintains Outperform Rating
2026-10-06 · 1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
2026-10-02 · Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
2026-09-30 · UBS Adjusts IQVIA Price Target to $345 From $240, Maintains Buy Rating
2026-09-29 · IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
Price (daily)
Full chart · RSI · MACD · patterns